NASDAQ:AXSM - Axsome Therapeutics Stock Price, Forecast & News

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics Inc (NASDAQ:AXSM) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.15. View Axsome Therapeutics' Earnings History.

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Axsome Therapeutics.

10 brokerages have issued 12-month price targets for Axsome Therapeutics' stock. Their forecasts range from $25.00 to $200.00. On average, they expect Axsome Therapeutics' share price to reach $99.80 in the next year. This suggests a possible upside of 14.8% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.

News headlines about AXSM stock have trended somewhat negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Axsome Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Axsome Therapeutics.

Axsome Therapeutics saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 5,030,000 shares, a decline of 6.0% from the December 15th total of 5,350,000 shares. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is currently 3.7 days. Currently, 17.9% of the shares of the company are sold short. View Axsome Therapeutics' Current Options Chain.

Some companies that are related to Axsome Therapeutics include Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), NVIDIA (NVDA), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), Viking Therapeutics (VKTX), Netflix (NFLX), AT&T (T) and Arrowhead Pharmaceuticals (ARWR).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.14%), Janney Montgomery Scott LLC (0.06%), Virginia Retirement Systems ET AL (0.04%), McAdam LLC (0.01%), UBP Investment Advisors SA (0.01%) and Huntington National Bank (0.00%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.

AXSM stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC and Virginia Retirement Systems ET AL. View Insider Buying and Selling for Axsome Therapeutics.

AXSM stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, McAdam LLC, UBP Investment Advisors SA, Huntington National Bank, Lindbrook Capital LLC and NEXT Financial Group Inc. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXSM stock can currently be purchased for approximately $86.97.

Axsome Therapeutics has a market capitalization of $3.00 billion. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.View Additional Information About Axsome Therapeutics.

The official website for Axsome Therapeutics is http://axsome.com/.

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.